Compounds that modulate intracellular calcium
AssigneeCalcimedica, Inc.
InventorsGonul Velicelebi, Kenneth A. Stauderman, David P. M. Pleynet, Soan Cheng, Jeffrey P. Whitten
Life of this patent
Estimating the term…
Abstract
Described herein are compounds and pharmaceutical compositions containing compounds of Formula (I), which modulate the activity of store-operated calcium (SOC) channels: wherein R1, R2 and R4 are defined herein. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
Claims9
A method of treating rheumatoid arthritis or ulcerative colitis in a mammal comprising administering to the mammal a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is hydrogen;
- R2 is aryl, benzothienyl, benzofuranyl, or —CH2CH2-phenyl;
- wherein R2 is optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, I, —CN, —NO2, —CF3, —OCF3, C1-C6alkyl, C3-C6cycloalkyl, C1-C6heteroalkyl, C1-C6haloalkyl, tetrazolyl, C2-C6heterocycloalkyl, phenyl, —NHS(═O)2R8, —S(═O)2N(R9)2, —C(═O)CF3, —C(═O)NHS(═O)2R8, —S(═O)2NHC(═O)R8, —N(R9)2, —N(R9)C(═O)R8, —CO2R9, —C(═O)R8, —OC(═O)R8, —CON(R9)2, —SR8, —S(═O)R8, and —S(═O)2R8
- R4 is an aryl, wherein the aryl is substituted with 1 or 2 substituents selected from F, Cl, Br, I, —CN, —NO2, —CF3, —OCF3, C1-C6alkyl, C3-C6cycloalkyl, C1-C6fluoroalkyl, C1-C6heteroalkyl, C1-C6haloalkyl, tetrazolyl, C2-C6heterocycloalkyl, phenyl, —NHS(═O)2R8, S(═O)2N(R9)2, —C(═O)CF3, —C(═O)NHS(═O)2R8, —S(═O)2NHC(═O)R9, N(R9)2, —N(R9)C(═O)R8, —CO2R9, —C(═O)R8, —OC(═O)R8, —C(═O)N(R9)2, —SR8, —S(═O)R8, and —S(═O)2R8;
- each R8 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, phenyl, and benzyl;
- and
- each R9 is independently selected from H, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, phenyl, and benzyl.
Dependencies are inferred from the claim text.